The report analyzes and forecasts the Alpha-1 antitrypsin deficiency treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of Alpha-1 antitrypsin deficiency treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Alpha-1 antitrypsin deficiency treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Alpha-1 antitrypsin deficiency treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of Alpha-1 antitrypsin deficiency treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Alpha-1 antitrypsin deficiency treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Alpha-1 antitrypsin deficiency treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Alpha-1 antitrypsin deficiency treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the non-vascular stents market, and profiled in the report include Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.
The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Treatment Type
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by End-User
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
Chapter 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
Chapter 3. Executive Summary:
3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot
3.2. Market Share Analysis by Region, 2018
Chapter 4. Market Overview
4.1. Market Overview
4.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Indicators
4.3. Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017–2026
4.4. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Outlook
Chapter 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increase in prevalence and incidence of respiratory diseases
5.2.2. Improved technology for production and purification methods
5.2.3. Rise in prescription of combination therapies
5.2.4. High R&D in asthma and COPD treatment
5.2.5. Increasing awareness programs
5.2.6. Favorable government initiatives and approvals
5.2.7. Rise in health care spending and improvement health care infrastructure
5.2.8. Development of better diagnostic methods
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Demand-supply gap
5.3.4. Limitation regarding reliable clinical data
5.3.5. Low diagnosis rate
5.4. Opportunities
5.4.1. Alternative potential therapies
5.4.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.5. Key Trends
5.6. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis
5.7. Comparative Brand Analysis
5.8. Porter’s Five Forces Analysis
5.9. Epidemiology: Alpha-1 Antitrypsin Deficiency
5.10. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
5.11. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
Chapter 6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment
6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment
6.3.1. Augmentation Therapy
6.3.1.1. Aralast
6.3.1.2. Prolastin
6.3.1.3. Zemaira/Respreeza
6.3.1.4. Glassia
6.3.2. Bronchodilator
6.3.3. Corticosteroids
6.3.4. Oxygen Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment
Chapter 7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user
7.1. Introduction
7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User
7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user
7.3.1. Specialty Clinics
7.3.2. Hospitals
7.3.3. Pharmacies
7.4. Market Attractiveness, by End-User
Chapter 8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration
8.1. Introduction
8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration
8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration
8.2.2. Parenteral
8.2.3. Inhalation
8.2.4. Oral
8.3. Market Attractiveness by Route of Administration
Chapter 9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region
9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook
9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region
9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region
9.4. Market Attractiveness Analysis, by Region
Chapter 10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
10.1. Market Overview
10.2. Market Analysis, by Treatment
10.2.1. Market Value Share Analysis, by Treatment
10.2.2. Market Size (US$ Mn) Forecast, by Treatment
10.2.2.1. Augmentation Therapy
10.2.2.1.1. Aralast
10.2.2.1.2. Prolastin
10.2.2.1.3. Zemaira/Respreeza
10.2.2.1.4. Glassia
10.2.2.2. Bronchodilator
10.2.2.3. Corticosteroids
10.2.2.4. Oxygen Therapy
10.2.2.5. Others
10.3. Market size (US$ Mn), by End-user
10.3.1. Market Value Share Analysis, by End-user
10.3.2. Market Size (US$ Mn) Forecast, by End-user
10.3.2.1. Specialty Clinics
10.3.2.2. Hospitals
10.3.2.3. Pharmacies
10.4. Market size (US$ Mn) Forecast, by Country
10.4.1. Market Value Share Analysis, by Country
10.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2026
10.4.2.1. U.S.
10.4.2.2. Canada
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country
Chapter 11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
11.1. Market Overview
11.2. Market Analysis, by Treatment
11.2.1. Market Value Share Analysis, by Treatment
11.2.2. Market Size (US$ Mn) Forecast, by Treatment
11.2.2.1. Augmentation Therapy
11.2.2.1.1. Aralast
11.2.2.1.2. Prolastin
11.2.2.1.3. Zemaira/Respreeza
11.2.2.1.4. Glassia
11.2.2.2. Bronchodilator
11.2.2.3. Corticosteroids
11.2.2.4. Oxygen Therapy
11.2.2.5. Others
11.3. Market size (US$ Mn), by End-user
11.3.1. Market Value Share Analysis, by End-user
11.3.2. Market Size (US$ Mn) Forecast, by End-user
11.3.2.1. Specialty Clinics
11.3.2.2. Hospitals
11.3.2.3. Pharmacies
11.4. Market size (US$ Mn) Forecast, by Country
11.4.1. Market Value Share Analysis, by Country
11.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2026
11.4.2.1. U.K.
11.4.2.2. Germany
11.4.2.3. France
11.4.2.4. Italy
11.4.2.5. Spain
11.4.2.6. Rest of Europe
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country
Chapter 12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
12.1. Market Overview
12.2. Market Analysis, by Treatment
12.2.1. Market Value Share Analysis, by Treatment
12.2.2. Market Size (US$ Mn) Forecast, by Treatment
12.2.2.1. Augmentation Therapy
12.2.2.1.1. Aralast
12.2.2.1.2. Prolastin
12.2.2.1.3. Zemaira/Respreeza
12.2.2.1.4. Glassia
12.2.2.2. Bronchodilator
12.2.2.3. Corticosteroids
12.2.2.4. Oxygen Therapy
12.2.2.5. Others
12.3. Market size (US$ Mn), by End-user
12.3.1. Market Value Share Analysis, by End-user
12.3.2. Market Size (US$ Mn) Forecast, by End-user
12.3.2.1. Specialty Clinics
12.3.2.2. Hospitals
12.3.2.3. Pharmacies
12.4. Market size (US$ Mn) Forecast, by Country
12.4.1. Market Value Share Analysis, by Country
12.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2026
12.4.2.1. Australia
12.4.2.2. Rest of Asia Pacific
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country
Chapter 13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
13.1. Market Overview
13.2. Market Analysis, by Treatment
13.2.1. Market Value Share Analysis, by Treatment
13.2.2. Market Size (US$ Mn) Forecast, by Treatment
13.2.2.1. Augmentation Therapy
13.2.2.1.1. Aralast
13.2.2.1.2. Prolastin
13.2.2.1.3. Zemaira/Respreeza
13.2.2.1.4. Glassia
13.2.2.2. Bronchodilator
13.2.2.3. Corticosteroids
13.2.2.4. Oxygen Therapy
13.2.2.5. Others
13.3. Market size (US$ Mn), by End-user
13.3.1. Market Value Share Analysis, by End-user
13.3.2. Market Size (US$ Mn) Forecast, by End-user
13.3.2.1. Specialty Clinics
13.3.2.2. Hospitals
13.3.2.3. Pharmacies
13.4. Market size (US$ Mn) Forecast, by Country
13.4.1. Market Value Share Analysis, by Country
13.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2026
13.4.2.1. Brazil
13.4.2.2. Mexico
13.4.2.3. Rest of LATAM
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country
Chapter 14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
14.1. Market Overview
14.2. Market Analysis, by Treatment
14.2.1. Market Value Share Analysis, by Treatment
14.2.2. Market Size (US$ Mn) Forecast, by Treatment
14.2.2.1. Augmentation Therapy
14.2.2.1.1. Aralast
14.2.2.1.2. Prolastin
14.2.2.1.3. Zemaira/Respreeza
14.2.2.1.4. Glassia
14.2.2.2. Bronchodilator
14.2.2.3. Corticosteroids
14.2.2.4. Oxygen Therapy
14.2.2.5. Others
14.3. Market size (US$ Mn), by End-user
14.3.1. Market Value Share Analysis, by End-user
14.3.2. Market Size (US$ Mn) Forecast, by End-user
14.3.2.1. Specialty Clinics
14.3.2.2. Hospitals
14.3.2.3. Pharmacies
14.4. Market size (US$ Mn) Forecast, by Country
14.4.1. Market Value Share Analysis, by Country
14.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2026
14.4.2.1. South Africa
14.4.2.2. Saudi Arabia
14.4.2.3. Rest of MEA
14.5. Market Attractiveness Analysis
14.5.1. By Treatment
14.5.2. By End-user
14.5.3. By Country
Chapter 15. Competition Landscape
15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2018)
15.2. Company Profiles
15.2.1. Grifols, S.A.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. AstraZeneca
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Teva Pharmaceutical Industries Ltd.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Boehringer Ingelheim GmbH
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. GlaxoSmithKline Plc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.6. CSL Behring LLC
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. Shire plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Pfizer Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. LFB Biomedicaments S.A.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
15.2.10. Kamada Ltd
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. SWOT Analysis
15.2.10.4. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers